OJBD  Vol.8 No.4 , December 2018
Surrogate Role of CD85k on Monocytic Lineage Involved Leukemogenesis Biology and Clinical Aspect
Background: Unique receptor involved in leukemogenesis is CD85k; an immuneglobulin receptor for immune tolerance, CD36 is glycoprotein mediates cellular adhesion and metastatic spread, CD14, CD15 considered common monocytic markers. Aims: to investigate CD85k with monocytic lineage involved leukemia (MLIL) markers in leukemia pathogenesis and clinical presentation. Patients and Methods: 47 patients (32 diagnosed acute myeloid leukemia (AML); 15 non-malignant hematological disease as a control), were included, aged from 2 to 80 years, all subjected to peripheral blood (P.Bl) and bone marrow (B.M) examination, immunophenotyping (IPT) using FASC Canto four color flow cytometer (FCM) Becton Dickenson (BD) USA, for CD13, CD33, MPO, HLA-DR, CD34, CD38, CD117, CD14, CD15 and CD36 the Mo Abs supplied by B.D Bioscience, and anti CD85k Mo Abs by Aveda de Coimbra Flamenco, reference No. 1399990130. Results: Frequency of CD85k is 19/32 (59.37%) of AML; 14/14 (M4/M5) 100% positive CD85k, insignificant correlations of CD85k to sex, lymphadenopathy or organomegaly, platelets count and P.Bl blast (P > 0.05), significant to age < 35 years, WBCs > 50,000 × 109/l, Hb < 7 g/dl, BM blasts, CD34 and HLA-DR CD33, CD13, CD38 (P < 0.05), insignificant correlations to CD36, CD14, CD15 and CD117 (P > 0.05). Conclusion: Although CD85k is MLIL associated marker, it is not correlated with other MLIL markers with frequency 100% in MLIL and 59.37% in AML, age predisposition is <35 years with no sex variation, significant correlation to progenitor and myeloid markers, it’s a crucial role in leukemogenesis biology, not in clinical presentations, considered good follow up predictor MLIL marker.
Cite this paper
Abo-Elwafa, H. , Aziz, S. , Ahmed, H. , Ali, E. and Elsaied, D. (2018) Surrogate Role of CD85k on Monocytic Lineage Involved Leukemogenesis Biology and Clinical Aspect. Open Journal of Blood Diseases, 8, 61-73. doi: 10.4236/ojbd.2018.84007.
[1]   Cheng, H., Mohammed, F., Nam, G., Chen, Y., Qi, J. and Garner, L.I. (2011) Crystal Structure of Leukocyte Ig-Like Receptor LILRB4 (ILT3/LIR-5/CD85k): A Myeloid Inhibitory Receptor Involved in Immune Tolerance. The Journal of Biological Chemistry, 286, 18013-18025.

[2]   Deng, M., Lu, Z., Zheng, J., Wan, X., Chen, X., Hirayasu, K., Sun, H., Lam, Y., Chen, L. and Wang, Q. (2014) A Motif in LILRB2 Critical for Angptl2 Binding and Activation. Blood, 124, 924-935.

[3]   Podrez, E.A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P.J., Shan, L., Gugiu, B., Fox, P.L., Hoff, H.F., Salomon, R.G. and Hazen, S.L. (2012) Identification of a Novel Family of Oxidized Phospholipids That Serve as Ligands for the Macrophage Scavenger Receptor CD36. Journal of Biological Chemistry, 277, Article ID: 3850316.

[4]   Zhang, Z., Hatano, H., Shaw, J., Olde Nordkamp, M., Jiang, G., Li, D. and Kollnberger, S. (2015) The Leukocyte Immunoglobulin-Like Receptor Family Member LILRB5 Binds to HLA-Class I Heavy Chains. PLoS One, 10, Article ID: e0129063.

[5]   Meyers, J., Yu, Y., Kaye, J.A. and Davis, K.L. (2013) Medicare Fee-For-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs. Applied Health Economics and Health Policy, 11, 275-286.

[6]   Matutes, E., Morilla, R. and Morilla, A.M. (2012) Immunophenotyping Immunological Markers in Acute Leukemia. In: Dacie and Lewis Practical Hematology, 11th Edition, Churchill Livingstone Elsevier, London, 362-364.

[7]   Jensen, M.A., Yanowitch, R.N., Reder, A.T., White, D.M, and Arnason, B.G. (2012) Immunoglobulin-Like Transcript 3, an Inhibitor of T Cell Activation, Is Reduced on Blood Monocytes during Multiple Sclerosis Relapses and Is Induced by Interferon Beta-1b. Multiple Sclerosis, 16, 30-38.

[8]   Han, L., Qiu, P., Zeng, Z., Cortes, J. and Steven, M. (2015) Single-Cell Mass Cytometry Reveals Intracellular Survival/Proliferative Signaling in FLT3-ITD-Mutated AML Stem/Progenitor Cells. Cytometry Part A, 87, 346-356.

[9]   Zhang, P., Yu, S., Li, H., Liu, C., Li, J., Lin, W., Gao, A., Wang, L., Gao, W. and Sun, Y. (2015) ILT4 Drives B7-H3 Expression via PI3K/AKT/m TOR Signaling and ILT4/B7-H3 Co-Expression Correlates with Poor Prognosis in Non-Small Cell Lung Cancer. Science China Life Sciences, 58, 1216

[10]   Kang, X., Kim, J., Deng, M., John, S., Chen, H., Wu, G., Phan, H. and Zhang, C. (2016) Inhibitory Leukocyte Immunoglobulin like Receptors Immune Checkpoint Protein and Tumor Sustaining Factors. Cell Cycle, 15, 25-40.

[11]   Miller, K.B. and Pihan, G. (2013) Clinical Manifestations of Acute Myeloid Leukemia. In: Hoffman, R., Benz, E.J., Shattil, S.J., Furie, B., Cohen, H.J., Silberstein, L.E., McGlave, P. and Heslop, H.E., Eds., Hematology Basic Principles and Practice, 5th Edition, Chapter 11, Elsevier, Amsterdam, 933-950.

[12]   Yonal, I., Hindilerden, F., Coskun, R., Dogan, O.L. and Nalcaci, M. (2011) A Leukemic Leukemia Cutis, the First Manifestation of Acute Myeloid Leukemia. Case Reports in Oncology, 4, 547-554.

[13]   Suciu-Foca, N., Vlad, G., Chang, C.-C., Liu, Z. and Colovai, A.L. (2013) Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand. Patentscope, WO/2013/033734.

[14]   Greer, J.P., Baer, M.B. and Kinney, M.C. (2012) Acute Myeloid Leukemia in Adults. In: Greer, J.P., Foerster, J., Rodgers, G.M., Paraskevas, F., Glader, B., Arder, D.A. and Means, R.T., Eds., Wintrobe’s Clinical Hematology, 12th Edition, Chapter 79, Lippincott Williams and Wilkins, Philadelphia, 1843-1888.

[15]   Lu, H.K., Rentero, C., Raftery, M.J., Raftery, M.J., Borges, L., Bryant, K. and Tedla, N. (2011) Leukocyte Ig-Like Receptor B4 (LILRB4) Is A Potent Inhibitor of FcgammaRI-Mediated Monocyte Activation via Dephosphorylation of Multiple Kinases. The Journal of Biological Chemistry, 284, 34839-34848.

[16]   Kang, X., Lu, Z., Cui, C., Deng, M., Fan, Y., Dong, B., Han, X., Xie, F., Tyner, J.W. and Coligan, J.E. (2015) The ITIM Containing Receptors LAIR1 Is Essential for Acute Myeloid Leukemia Development. Nature Cell Biology, 17, 665-677.

[17]   Sharma, P. and Allison, J.P. (2015) Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell, 161, 205-214.

[18]   Gupta, A., Pal, A. and Nelson, S.S. (2015) Immunophenotyping in Acute Leukemia: A Clinical Study. International Journal of Scientific Study, 3, 129-136.

[19]   Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M. and Vardiman, J.W. (2016) The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood, 127, 2391-2405.

[20]   Deschler, B., Ihorst, G., Uwe, P., Platzbecker, U. and Lübbert, M. (2013) Parameters Detected by Geriatric and Quality of Life Assessment in 195 Older Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Are Highly Predictive for Outcome. Haematologica, 98, 208-216.

[21]   Ghosh, S., Shinde, S.C., Kumaran, G.S., Sapre, R.S., Dhond, S.R. and Badrinath, Y. (2003) Haematologic and Immunophenotypic Profile of Acute Myeloid Leukemia. An Experience of Tata Memorial Hospital. Indian Journal of Cancer, 40, 71-76.

[22]   Dobrowolska, H., Gill, K.Z., Serban, G., Ivan, E., Lio, Q., Qiao, P., Suciu-Foca, N., Savage, D., Alobeid, B., Bhagat, G. and Colovia, A.I. (2013) Expression of Immune Inhibitory Receptor ILT3 in Acute Myeloid Leukemia with Monocytic Differentiation. Cytometry Part B: Clinical Cytometry, 84, 21-29.

[23]   Cagnetta, A., Adamia, S., Acharya, C., Patrone, F., Miglino, M. and Nencioni, A. (2014) Role of Genotype-Based Approach in the Clinical Management of Adult Acute Myeloid Leukemia with Normal Cytogenetics. Leukemia Research, 38, 649-659.

[24]   Betz, B.L. and Hess, J.L. (2015) Acute Myeloid Leukemia Diagnosis in the 21st Century. Archives of Pathology & Laboratory Medicine, 134, 1427-1433.

[25]   Boer, J.M., Veer, A.V., Rizopoulos, D., Fiocco, M., Sonneveld, E., Stanulla, M. and Conter, V. (2016) Prognostic Value of Rare IKZF1 Deletion in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. Leukemia, 30, 32-38.